Hyloris Teams Up With Vaneltix For Value-Added Interstitial Cystitis Pain Treatment

Results From Phase II Trials For Lidocaine/Heparin Candidate Could Be Ready By Late 2023

 
• By Chloe Kent
  
Handshake
Hyloris will make payments of up to $6.7m to Vaneltix, alongside a $500,000 loan, to support their collaboration • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business